SequelSEC

BIOFORCE NANOSCIENCES HOLDINGS, INC. BFNH

Laboratory Analytical Instruments · CIK 0001310488 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2019-12-31
Operating income
-$20.17K
Fiscal year ended 2019-12-31
Free cash flow
Unavailable
Fiscal year ended 2019-12-31

Valuation, from the filing

Public float$2.63MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.08Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the Laboratory Analytical Instruments filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin24.5%0th
Net margin-261.8%18th
Revenue YoY growth9.0%82th
Current ratio5.08x65th

BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) reported revenue of $0 and net income of -$20.17K for the fiscal year ended 2019-12-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from BIOFORCE NANOSCIENCES HOLDINGS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Laboratory Analytical Instruments.

Income

BIOFORCE NANOSCIENCES HOLDINGS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302017-12-31
Revenue$0$5.96K$5.96K$5.85K$5.74K$5.51K$5.06KUnavailable
Cost of revenue$0$4.24K$5.02K$4.16K$4.08K$3.92K$3.64KUnavailable
Gross profit$0$1.72K$947$1.69K$1.66K$1.59K$1.42KUnavailable
Operating income-$20.17K-$6.33K-$7.18K-$12.85K-$8.59K-$6.64K-$27.53KUnavailable
Net income-$20.17K-$6.33K-$7.18K-$12.85K-$8.59K-$6.64K-$28.53KUnavailable
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$20.17K-$6.33K-$7.18K-$12.85K-$8.59K-$6.64K-$28.53KUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$20.17K$8.06K$8.13K$14.54K$10.25K$8.24K$28.95KUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

BIOFORCE NANOSCIENCES HOLDINGS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302017-12-31
Cash & equivalents$52.90K$46.93K$40.97K$35.12K$29.39K$23.89K$23.88K$14.32K
Total assets$58.90K$52.89K$46.93K$40.97K$35.13K$29.40KUnavailable$20.91K
Current assets$58.90K$52.89K$46.93K$40.97K$35.13K$29.40KUnavailable$20.91K
Total liabilities$11.59K$4.54K$5.02K$6.78K$5.32K$5.46KUnavailable$12.71K
Current liabilities$11.59K$4.54K$5.02K$6.78K$5.32K$5.46KUnavailable$12.71K
Total equity incl. NCI$47.31K$48.35K$41.92K$34.20K$29.80K$23.94K$16.34K$8.20K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailable$5.96K$5.96K$5.85K$5.74K$5.51KUnavailable$4.50K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

BIOFORCE NANOSCIENCES HOLDINGS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302017-12-31
Operating cash flow-$10.26K-$1.79K-$4.89K-$7.44K-$5.04K-$10.58KUnavailableUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow$16.22K$7.76K$10.74K$13.16KUnavailableUnavailableUnavailableUnavailable
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

BIOFORCE NANOSCIENCES HOLDINGS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302017-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailable28.9%15.9%28.9%28.9%28.9%28.0%Unavailable
Operating marginUnavailableUnavailableUnavailableUnavailable-149.9%-120.5%-543.8%Unavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio5.08x11.65x9.36x6.05x6.60x5.38xUnavailable1.65x
Revenue YoY growth-100.0%8.2%17.8%UnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailable-106.2%-120.5%-219.7%-149.9%-120.5%-563.6%Unavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BFNH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-19View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-19View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.